These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30636434)

  • 1. Acute agranulocytosis when switching from risperidone to paliperidone.
    Wakuda T; Suzuki A; Hasegawa M; Ichikawa D; Yamasue H
    Aust N Z J Psychiatry; 2019 Jun; 53(6):586-587. PubMed ID: 30636434
    [No Abstract]   [Full Text] [Related]  

  • 2. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
    [No Abstract]   [Full Text] [Related]  

  • 3. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 4. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 5. The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate.
    Omer HM; Thompson AD
    Aust N Z J Psychiatry; 2018 May; 52(5):496-497. PubMed ID: 29338294
    [No Abstract]   [Full Text] [Related]  

  • 6. Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E36-7. PubMed ID: 24763786
    [No Abstract]   [Full Text] [Related]  

  • 7. Paliperidone-Associated Atrioventricular Block.
    Yasin M; Lateef N; Pervaiz MH
    Am J Ther; 2018; 25(6):e730-e732. PubMed ID: 29528883
    [No Abstract]   [Full Text] [Related]  

  • 8. Paliperidone-Induced Hyponatremia.
    Tibrewal P; Dhillon R; Sharma J; Bastiampillai T
    Prim Care Companion CNS Disord; 2017 Jul; 19(4):. PubMed ID: 28767207
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
    Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
    Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preclinical discovery and development of paliperidone for the treatment of schizophrenia.
    Wesołowska A; Jastrzębska-Więsek M; Cios A; Partyka A
    Expert Opin Drug Discov; 2020 Mar; 15(3):279-292. PubMed ID: 31661992
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patient's Gestation Period.
    Zamora Rodríguez FJ; Benítez Vega C; Sánchez-Waisen Hernández MR; Guisado Macías JA; Vaz Leal FJ
    Pharmacopsychiatry; 2017 Jan; 50(1):38-40. PubMed ID: 27414740
    [No Abstract]   [Full Text] [Related]  

  • 12. Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up.
    Singh S; Gupta A; Kuppili PP; Pattanayak RD; Khandelwal SK
    J Clin Psychopharmacol; 2016 Aug; 36(4):391-3. PubMed ID: 27269958
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Facial Dystonia (Meige or Brueghel Syndrome) Induced by Paliperidone Palmitate.
    Marques JG
    Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28129491
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.
    Legrand G; Andrianarisoa M; Mauvieux J; Jalenques I
    J Clin Psychopharmacol; 2014 Oct; 34(5):652-3. PubMed ID: 25006816
    [No Abstract]   [Full Text] [Related]  

  • 16. Paliperidone Injection-Associated Delayed-Onset Rash.
    Sundling K; Held J; Narang P; Lippmann S
    Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30817863
    [No Abstract]   [Full Text] [Related]  

  • 17. Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.
    Su JA; Wu CH; Tsang HY
    Gen Hosp Psychiatry; 2007; 29(1):75-7. PubMed ID: 17189752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for psychotic disorders.
    Med Lett Drugs Ther; 2016 Dec; 58(1510):160-164. PubMed ID: 27960194
    [No Abstract]   [Full Text] [Related]  

  • 19. Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
    Tagne Nouemssi AB
    BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29680794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.